GSK's asthma and COPD treatment 'Relvar Ellipta’ received sales approval from the Ministry of Food and Drug Safety
GSK's asthma and chronic obstructive pulmonary disease (COPD) treatment 'Relvar Ellipta (fluticasone furoate + vilanterol), received sales approval from the Ministry of Food and Drug Safety.
'Relvar' is composed of inhaled corticosteroid (ICS) fluticasone furoate and long-acting beta-2 agonist (...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
